Bio-Path Holdings (BPTH)
OTHER OTC:BPTH
Want to see BPTH full AI Analyst Report?
BPTH Stock Chart & Stats
$0.05
-$0.06(-5.61%)
At close: 4:00 PM EST
$0.05
-$0.06(-5.61%)
Day’s Range― - ―
52-Week Range$0.01 - $0.23
Previous CloseN/A
Volume216.71K
Average Volume (3M)24.92K
Market Cap
$1.76M
Enterprise Value$779.26K
Total Cash (Recent Filing)$12.00K
Total Debt (Recent Filing)$511.00K
Price to Earnings (P/E)―
Beta-0.66
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding50,297,450
10 Day Avg. Volume24,655
30 Day Avg. Volume24,916
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.06
Price to Sales (P/S)0.00
P/FCF Ratio-0.30
Enterprise Value/Market Cap0.44
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-11.46
Enterprise Value/Ebitda-0.14
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.42
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Delivery PlatformBio-Path's proprietary liposomal delivery (DNAbilize) and antisense/siRNA-like platform represent a durable technical moat for RNAi oncology programs. A reliable delivery system increases the odds of clinical readthrough, enables multiple pipeline candidates across indications, and boosts licensing or partnership appeal over the medium term.
Low Absolute Debt BurdenVery low reported debt reduces near-term interest and refinancing pressure, preserving optionality for clinical spending or strategic transactions. Structurally, limited fixed obligations give management flexibility to prioritize trials or seek partnerships without immediate solvency constraints.
Meaningful Reduction In Cash Burn (2025)A materially smaller operating/free cash outflow in 2025 indicates improved cost control or program prioritization that can extend runway. If sustained, lower burn reduces reliance on frequent dilutive financings and improves the company's ability to reach clinical inflection points or negotiate collaborations with less immediate capital pressure.
Bears Say
No Product RevenueThe company remains fully development-stage with no commercial sales, so operating cash needs are structural until regulatory approval or licensing occurs. Persistent net losses mean continued cash consumption; the absence of recurring revenue leaves long-term viability tied to successful trials or external funding events.
Negative Shareholders' EquityNegative equity signals significant capital depletion and weakens balance-sheet resilience. This structural deterioration can limit borrowing capacity, raise counterparty concerns, and make future financing more dilutive or costly, constraining strategic options during clinical development phases.
Reliance On External FinancingHistoric dependence on equity and financing activities to fund operations is a structural vulnerability. Until commercial revenues or large licensing deals materialize, the company faces recurring dilution risk and timing mismatch with capital markets, increasing execution risk for multi-year clinical programs.
Bio-Path Holdings News
BPTH FAQ
What was Bio-Path Holdings’s price range in the past 12 months?
Bio-Path Holdings lowest stock price was $0.01 and its highest was $0.23 in the past 12 months.
What is Bio-Path Holdings’s market cap?
Bio-Path Holdings’s market cap is $1.76M.
When is Bio-Path Holdings’s upcoming earnings report date?
Bio-Path Holdings’s upcoming earnings report date is Aug 18, 2026 which is in 72 days.
How were Bio-Path Holdings’s earnings last quarter?
Bio-Path Holdings released its earnings results on May 08, 2026. The company reported -$0.029 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.029.
Is Bio-Path Holdings overvalued?
According to Wall Street analysts Bio-Path Holdings’s price is currently Overvalued.
Does Bio-Path Holdings pay dividends?
Bio-Path Holdings does not currently pay dividends.
What is Bio-Path Holdings’s EPS estimate?
Bio-Path Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bio-Path Holdings have?
Bio-Path Holdings has 50,297,450 shares outstanding.
What happened to Bio-Path Holdings’s price movement after its last earnings report?
Bio-Path Holdings reported an EPS of -$0.029 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.091%.
Which hedge fund is a major shareholder of Bio-Path Holdings?
Currently, no hedge funds are holding shares in BPTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bio-Path Holdings
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.50% Other Institutional Investors
99.50% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---